Seres : Phase 3 Study Shows SER-109 Associated With Reduction Of ARGs In Patients With Recurrent CDI
3/10 04:30
(RTTNews) - Seres Therapeutics Inc.'s (MCRB) SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection or rCDI, was associated with significantly greater reduction of antimicrobial resistance genes or ARGs compared to placebo, with the reductio...